Apr 04, 2017 11:00 am UTC| Business
LOS ALTOS, Calif., April 04, 2017 -- DSP Group®, Inc. (NASDAQ:DSPG), a leading global provider of wireless chipset solutions for converged communications, and Emza Visual Sense, announced today the industry’s first...
BIOPHYTIS secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT
Apr 04, 2017 11:00 am UTC| Business
Completes €3.7 million private placementArranges a bond financing of €15 million PARIS, April 04, 2017 -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to...
Sportsman's Warehouse Stores Host 7th Annual National Ladies' Night Event
Apr 04, 2017 11:00 am UTC| Business
MIDVALE, Utah, April 04, 2017 -- Sportsman’s Warehouse (Nasdaq:SPWH) -- Sportsman's Warehouse retail stores nationwide will host the 7th Annual Ladies' Night on Thursday, April 6, 2017. This event will celebrate the...
Apr 04, 2017 11:00 am UTC| Business
SCOTTSDALE, Ariz., April 04, 2017 -- Meritage Homes Corporation (NYSE:MTH), a leading U.S. homebuilder, plans to release the Company's first quarter 2017 results on Thursday, April 27, 2017 before the market opens....
BrainJuicer Rebrands as System1 Group
Apr 04, 2017 11:00 am UTC| Business
NEW YORK and LONDON, April 04, 2017 -- BrainJuicer today announces that it has rebranded as System1 Group, PLC. System1 Group is comprised of System1 Agency and System1 Research, and its mission is to produce and...
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
Apr 04, 2017 11:00 am UTC| Business
WALTHAM, Mass., April 04, 2017 -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...
VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
Apr 04, 2017 11:00 am UTC| Business
TEL AVIV, Israel, April 04, 2017 -- VBL Therapeutics (NASDAQ:VBLT), announced today the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study, entitled "MOSPD2, a Newly Characterized...